Amicus: Teva Settlement Clears Revenue Path Forward For Galafold
Amicus Therapeutics settled litigation with Teva, preventing a generic version of Galafold for Fabry Disease until 2037, ...
Zacks.com on MSN9h
FOLD Stock Rises on Settling Galafold Patent Dispute With Teva
Amicus also has a second FDA-approved drug in its commercial portfolio. In September 2023, the FDA approved Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) 65mg capsules, a two-component ...
PTC rebuffed again by EMA; Novartis licenses China-based biotech’s cancer drug
European regulators have for the fourth time issued a negative opinion on PTC's Translarna. Elsewhere, Amylyx read out data ...
Keep Your Home Free From Stink Bugs with These Top-Rated Stink Bug Repellents
Use the best stink bug repellent to keep these stinky pests (and other pests) away from your house. See which products made ...